Hi Skip,

I have been sending you email but I never get any answers from you. I think
there is  something wrong with your email???

I'm glad to learn that your feeling better.

Still waiting on a kidney transplant. Nothing yet.

18's

Marty


On Wed, Apr 17, 2013 at 1:20 PM, Skip Duffie <skipd_2...@yahoo.com> wrote:

>
>   Hello Marty, and all
> sorry I have not been keeping tabs with the Groups but I have been rather
> ill for a while, although I must admit
> today I feel much better today than in months.  going back over me email I
> do not see much in the way of email, is there a problem
> with what I receive or is it that cml 2 and hope are just being quiet...
> MARTY how are you feeling, I do hope your well. Anyway I am slowly getting
> back
> SkipD
>
>
>
>
>
> *From:* Marty Gartenberg <wa2...@gmail.com>
> *To:* cmlhope@googlegroups.com
> *Sent:* Tuesday, April 16, 2013 11:20:06 AM
> *Subject:* Re: [CMLHope] Re: Gleevec patent coming to an end in U.S. soon
>
> Hi Peg and everyone else.
>
> Just so you know, Novartis was sued by some people in India over the
> patent rights of Gleevec and they won the law suit. Now, this means that
> India is now allowed to use a generic drug instead of the original Gleevec.
>
> So, with this said, Gleevec may just become a thing of the past with a
> generic drug  and ends up costing much less.
>
> 18's (symbol for life)
>
> Marty
>
>
>
>
> On Tue, Apr 16, 2013 at 9:37 AM, peg <peg....@live.com> wrote:
>
> Hi All,
>
> Been out of the loop for a while, but wanted to add my two cents to this
> post about Gleevec patent.  The end of the patent on any TKI is going to be
> a mixed bag.  While the development of a generic will dramatically bring
> the cost down on that generic, it will pose a real problem for those on the
> other TKI's still under patent.  Once the cost playing field is no longer
> level, you will find that insurance formularies will no longer approve the
> non-generic TKI's, opting for the lower cost one...under the assumption
> that all TKI's are equal.  While some folks will fight for and be granted
> exceptions, based on previous trial with Gleevec, others of us will not.
>  To grant an exception is to the discretion of the insurance company.  The
> idea that all TKI's are equal is a wide-spread idea in many countries, some
> refusing to grant use of TKI's that the manufacturer would not negotiate
> lower pricing.  While there is always patient assistance programs
> available, only some will qualify, and even then just having to go through
> that change will be unnerving for those of us who's live depend on the drug
> we are currently taking.  Like always, we must be careful what we wish for!
>
>
> Warmest regards to everyone!
>
> peg
> Currently PCRU on Sprycel 50mg every other day.
>
> On Monday, March 11, 2013 11:30:24 AM UTC-7, Vivi wrote:
>
> Unfortunately, the U.S. Food and Drug Administration is making it
> extremely difficult for bio-similar generic drugs to be produced and
> marketed in the U.S.  I'm not familiar with the regulations in Canada but
> it's possible we won't see a generic of Gleevec all that soon in the U.S.
>
> --
> --
> [CMLHope]
> A support group of http://cmlhope.com/
> -------------------------------------------------
>
> You received this message because you are subscribed to the Google Groups
> "CMLHope" group.
> To post to this group, send email to CMLHope@googlegroups.com
> To unsubscribe from this group, send email to
> cmlhope-unsubscr...@googlegroups.com
> For more options, visit this group at
> http://groups.google.com/group/CMLHope
> ---
> You received this message because you are subscribed to the Google Groups
> "CMLHope" group.
> To unsubscribe from this group and stop receiving emails from it, send an
> email to 
> mailto:cmlhope%2bunsubscr...@googlegroups.com<cmlhope%2bunsubscr...@googlegroups.com>
> .
> For more options, visit https://groups.google.com/groups/opt_out.
>
>
>
>
> --
> --
> [CMLHope]
> A support group of http://cmlhope.com/
> -------------------------------------------------
>
> You received this message because you are subscribed to the Google Groups
> "CMLHope" group.
> To post to this group, send email to CMLHope@googlegroups.com
> To unsubscribe from this group, send email to
> cmlhope-unsubscr...@googlegroups.com
> For more options, visit this group at
> http://groups.google.com/group/CMLHope
> ---
> You received this message because you are subscribed to the Google Groups
> "CMLHope" group.
> To unsubscribe from this group and stop receiving emails from it, send an
> email to cmlhope+unsubscr...@googlegroups.com.
> For more options, visit https://groups.google.com/groups/opt_out.
>
>
>
>
>    --
> --
> [CMLHope]
> A support group of http://cmlhope.com
> -------------------------------------------------
>
> You received this message because you are subscribed to the Google Groups
> "CMLHope" group.
> To post to this group, send email to CMLHope@googlegroups.com
> To unsubscribe from this group, send email to
> cmlhope-unsubscr...@googlegroups.com
> For more options, visit this group at
> http://groups.google.com/group/CMLHope
> ---
> You received this message because you are subscribed to the Google Groups
> "CMLHope" group.
> To unsubscribe from this group and stop receiving emails from it, send an
> email to cmlhope+unsubscr...@googlegroups.com.
> For more options, visit https://groups.google.com/groups/opt_out.
>
>
>

-- 
-- 
[CMLHope]
A support group of http://cmlhope.com
-------------------------------------------------

You received this message because you are subscribed to the Google Groups 
"CMLHope" group.
To post to this group, send email to CMLHope@googlegroups.com
To unsubscribe from this group, send email to 
cmlhope-unsubscr...@googlegroups.com
For more options, visit this group at http://groups.google.com/group/CMLHope
--- 
You received this message because you are subscribed to the Google Groups 
"CMLHope" group.
To unsubscribe from this group and stop receiving emails from it, send an email 
to cmlhope+unsubscr...@googlegroups.com.
For more options, visit https://groups.google.com/groups/opt_out.


Reply via email to